• Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage
• The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device
• Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion
• In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate

Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions that offer clinical advantages to unmet medical needs. The company boasts a repertoire of several products that include the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device, both of which are in development and are, therefore, not yet commercially available, as well as a novel breath-propelled nasal delivery device designed to deliver the company’s novel treatment for concussion, PRV-002. Nasal Delivery Device The nasal delivery device, which was the subject of a patent application filed last fall (https://ibn.fm/9c2KZ), is part of a drug-device combination that is being used in Odyssey’s ongoing Phase I clinical trial investigating how well PRV-002 is tolerated by healthy human subjects. “It’s a small device that essentially delivers a powdered drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within 5 minutes and spreads out throughout the brain within 30 minutes, reversing the effects of a concussion,” explained Odyssey CEO Michael Redmond in a recent interview with RedChip Companies CEO Dave Gentry (https://ibn.fm/Pz8SE). The device provides Odyssey with the opportunity to get PRV-002 into the brain rapidly after a concussion, a factor that, coupled with the drug’s safety profile and lack of adverse side effects as indicated by extensive animal trials and initial results from a section of the participants in the Phase I clinical trial, will be instrumental to the company’s success in its clinical trials. PRV-002 Novel Drug Candidate Developed by two neuroscientists, one of whom has a background as a toxicologist, PRV-002 is a compound that Redmond described as a drug cocktail containing three new, proprietary elements that have three mechanisms of action. “Between the two of them, having both toxicology and neurological backgrounds, they created an extremely safe drug compound. We did animal studies that show even at 200 times what we believe to be the dosing, there’s still no toxicity. So, it’s an extremely safe drug, and the efficacy in the animal models is very strong. We have confidence that this will translate into humans,” Redmond continued. The PRV-002 drug is designed to be administered as close to a concussion event as possible, with quicker administration leading to better results. Odyssey has established that there is a window of at least six hours within which the drug shows greater efficacy, if administered. To boost the chances of greater efficacy from quick administration, the PRV-002 drug candidate is available as a dry powder with a long shelf life and does not require special handling or refrigeration. For this reason, it can sit on the sidelines of any football game or sporting event. In addition, soldiers, who are at great risk of suffering blunt trauma from explosives’ shockwaves, bullet penetration, and violent impact, can store it in their backpacks, while emergency response teams can keep it in their ambulances or emergency rooms (“ERs”). When asked how quickly the company expects to begin Phase II clinical trials given the ongoing Phase I clinical trial, Redmond noted, “When we have the Phase I data, we can actually start a Phase II trial in Australia immediately. We have a site set to start a Phase II trial in Australia, likely in the October timeframe. We want to do some of the Phase II or most of it in the U.S., and that requires FDA approval. We have reached out to the FDA to set up that meeting, and hopefully, we’ll have a meeting with the FDA where we can provide our Phase I data in the summer timeframe.” The company is in discussions with the military in the U.S. to undertake the Phase II study at some of the military sites that experience a large number of concussions and has, in fact, formed a Military Advisory Board to help it achieve this goal (https://ibn.fm/j4LAw). Odyssey expects to “be in the U.S. Phase II [clinical trial stage] this year, probably in the fourth quarter,” subject to FDA approval. Strategic Approach Odyssey has strategically planned its Phase II trial to ensure it collects data as soon as the study commences. According to Redmond, the ability to gather data is a function of the number of concussed patients, meaning the company has to set trials at sites that report a high number of concussions. For example, the military has at least two sites that experience over 100 concussions a month. And by setting up the trials at these sites, the company expects to start collecting data immediately upon the start of the trial. Redmond also highlighted the subsequent phases of its drug development journey, noting that the drug could be available for commercialization to Special Populations – a group of people, in this case, the military, that experiences concurrent disease states (https://ibn.fm/O9jh7) – immediately after a successful Phase II trial. That’s because there is currently no FDA-approved treatment for concussion. To facilitate this milestone, Odyssey would be open to partnerships for commercialization, marketing, and distribution. For more information, visit the company’s website at https://odysseygi.com/. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• New meal plan offering includes three meals a day (breakfast, lunch and dinner) up to five days per week
• Model Meals brand is optimal for providing seamless customer experience, substantially increased customer lifetime value
• Move provides opportunity to explore subscription model with other HBIS components, says CEO

Home Bistro (OTC: HBIS), a leading online meal-delivery platform that offers exclusive celebrity chef-inspired, gourmet and lifestyle ready-made meals, is strengthening its commitment to offer exclusive celebrity-chef-inspired, ready-made meals by launching its first subscription-based offering for its Model Meals brand (https://ibn.fm/9wDv9). The new plan offering includes three meals a day (breakfast, lunch and dinner) up to five days per week. “We are excited to finally execute on a long-term strategic objective by establishing a subscription-based meal platform,” said Zalmi Duchman, Home Bistro CEO. “We believe the Model Meals lifestyle brand is optimal for establishing a sticky, recurring revenue model, which provides for a seamless customer experience and a substantially increased customer lifetime value. This also gives us an opportunity to explore the subscription model with other components of our business.” Initially HBIS will offer the subscription-based plans in its southern California market, with plans to expand moving forward. Home Bistro acquired Model Meals in July 2021 in a strategic move to extend its food-production and fulfillment capabilities to the western region of the United States (https://ibn.fm/0JwbH). “This acquisition provides Home Bistro with major benefits on multiple levels,” said Home Bistro CEO Zalmi Duchman. “First, given our now bicoastal operations, we have the ability to ship overnight to most customers within the 48 contiguous states. Next, we acquired a lifestyle brand that has the potential for recurring revenue, subscription-based enrollment and potential for growth to the other 47 states from the current three. Lastly, we add tremendous talent to the Home Bistro management team with Camille, Danika and the senior staff at Model Meals.” Home Bistro’s Model Meals lifestyle brand is a Whole30- and Paleo-approved, ready-to-eat, meal-prep service (https://ibn.fm/RVPRO). The platform offers a weekly menu that rotates. Meal plans are prepared by professional chefs, using only the highest-quality ingredients available, which are sourced responsibly and locally, and delivered in sustainable, ecofriendly packaging. The strategic movement by HBIS comes as a Mordor Intelligence study reports that the “the global ketogenic diet food market is projected to register a CAGR of 5.52% during the forecast period, 2022—2027” (https://ibn.fm/cwJMh). The report notes that the global pandemic and the fact that “online health training websites and various social media platforms have been promoting to intake of healthy diets . . . has increased the consumption of keto-based food and beverage at a faster growth.” For more information, visit the company’s website at www.HomeBistro.com. NOTE TO INVESTORS: The latest news and updates relating to HBIS are available in the company’s newsroom at https://ibn.fm/HBIS

• Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance
• Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics
• Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO

New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that preliminary data from the study indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research. “Previously, studies had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” Drysdale continued. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.” Cybin is partnering with Kernel, a leader in noninvasive neuroimaging, for the study. During the study, participants receive either a low dose of ketamine or a placebo while wearing the Flow headset, which measures cortical hemodynamics experienced during an altered state of consciousness. Data was collected to create a baseline at days 1 through 5, with a dosing administered at day 6, then follow-up data was collected on days 7 through 11, confirming that ketamine-induced changes in functional connectivity lasted for several days after participants received the substance. “Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Bryan Johnson, Founder and Chief Executive Officer of Kernel. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help advance these powerful new therapies for patients.” The feasibility study involves participants wearing Kernel Flow, which features hi-tech sensors to record brain activity, while in an altered state of consciousness following the administration of ketamine. The system records brain activity throughout the four-week study, which is combined with information gathered from questionnaires and validated assessments. Information from the study may be used by Cybin as it develops its two active drug programs, CYB003 and CYB004, which target anxiety and depression (https://ibn.fm/nULws), (https://ibn.fm/gQjHz). CYB003 is a deuterated psilocybin analog derived from psilocybin that is designed to achieve less variability in plasma levels, a faster onset of action and shorter duration of effect, as well as potentially better tolerability, for an overall better outcome for patients. CYB004 is a deuterated dimethyltryptamine (“DMT”) that, in its natural form, is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies show the potential for overcoming these limitations such that deuterated DMT could provide increased oral and pulmonary bioavailability and faster onset, with lower doses, less patient variability, and better dose titration, resulting in fewer side effects and longer-acting desensitization of the serotonergic receptors. CYB004 is also being evaluated for its potential to effectively treat anxiety disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

Sustain Southern California (“Sustain SoCal”) accelerates cleantech economic growth and sustainability initiatives through innovation, collaboration, and education. Sustain SoCal is hosting Driving Mobility – the 9th Annual Transportation Conference. This year’s event will feature succinct presentations by leading c-suite executives, senior management, and industry experts from public sector organizations. Invited speakers will share their perspectives on a multitude of issues, including electrification, V2X, hydrogen/fuel cell, OEM and investor trends, connected vehicles, mobility as a service, incentives, policy, legislation, and sustainability. Mobility and transportation experts, representatives of local and state authorities, potential investors from private equity and venture capital, experts from the battery storage subsector, university faculty, and senior executives from marquee companies such as Virgin Galactic and Volvo N.A., that specialize in mobility and transportation will be in attendance. Key aspects of this event:

• Driving Mobility 9 is a one-day in-person event. The conference will be from 1:00-5:00 pm and the EXPO and reception will be held from 5:00-7:30 pm
• The event will take place at UCI Beall Applied Innovation
• The event is free of cost for Sustain SoCal Members.
• Presentations will be brief, packed with information, insights, and to the point.
• The event will also host an Innovators Showcase, where c-suite executives will present their latest research and development to attendees.
• An in-person EXPO and reception will be held to conclude the event.

Who’s Organizing This Event? Sustain SoCal is a non-profit organization based at UCI Beall Applied Innovation, that proactively addresses Southern California’s sustainability, environmental and infrastructure needs and objectives. The organization gathers stakeholders via industry-leading conferences, workshops, and networking events to positively impact the region’s economic progress and sustainable future. During its long history, Sustain SoCal has focused on key sectors such as Energy, Water, Agriculture, Transportation, Hospitals and Healthcare, and Waste Stream Management. The organization aims to foster cooperation and collaboration among the public, private and academic sectors in the area of sustainability and cleantech within and around the greater Southern California region while serving as an information hub, a platform for advocacy, and providing mentorship and advisory with a view to further sustainable linkages. Sustain SoCal invites established and emerging cleantech companies, start-up companies, corporate organizations of all sizes, municipal/regional/state/national agencies, non-profit organizations, and investors to register for the event. Why Should You Attend? The Driving Mobility 9 event presents a unique opportunity to build a deep understanding of the evolving trends in mobility and advanced transportation. The event will host several industry stalwarts and sector experts, who will provide an insightful commentary on the state of the sector and future opportunities. Attendees will be able to learn from and interact directly with thought leaders across various sub-sectors in the mobility and transportation landscape. Furthermore, the event will provide a forum for exchanging ideas and exploring business opportunities and enable networking with large corporations, cleantech companies, local government, investors, academia, and non-profits. In addition, it will provide a platform to share best practices, a deeply educational experience for the broader community to engage with clean technology, and potential financial opportunities for investment professionals. How To Register? For more information on the event, visit here. To register, please submit the registration form at the earliest. For SoCal members, the event is free. So why wait?

• Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated
• The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd
• No additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus counts
• The reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking

The COVID-19 pandemic, from the start, has been characterized by the high unpredictability of the virus. Despite the best efforts of the scientific community to use the historical data and patterns of previous viruses, it is becoming apparent that the original presumptions are no longer valid. The original hypothesis was that once enough people created an immunity to COVID-19, it would stop the virus dead in its tracks; unfortunately, what they are learning is that herd immunity is unlikely to happen. Herd immunity occurs when a virus can’t spread because it keeps encountering people who have become immune to the specific virus. The idea is that a small group of people lacking resistance to the virus can be protected by the immune herd because it is less likely to spread to them. Even though the mentality that herd immunity can be successful through immunizations, scientists no longer believe that this is an appropriate management strategy for COVID-19 long-term. Two years after a COVID-19 vaccine was made available, fewer than 70% of Americans are fully vaccinated (https://ibn.fm/lcOKY). The pockets of unvaccinated people who lack any type of immunity to this ever-changing virus only provide the potential for the virus to grow and mutate as it spreads. Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). The score can be used to provide those tested with important answers to questions like:

• Are antibodies present?
• How are these antibodies present – vaccine or natural immune system response?
• Will this immunity status provide protection from the virus in the future?
• What is the best approach to creating immunity for that individual?

“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/pbmD3). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.” With the potential for herd immunity off the table, and federal COVID funds dwindling, supply rationing has begun. Of the current budget, the Biden Administration has reallocated $5 billion to purchase updated versions of the vaccine for fall. Since Congress has approved no new funding, the Administration is forced to use the remaining budget to consider the longer-term solutions, like fall when virus uptick increases. At this time, epidemiologists are concerned about the blind spots created due to the shift in focus from testing to more vaccine development. Without the increased testing efforts, it becomes impossible to track and isolate variants. Without the funding, further development on the COVID-19 front will be less likely to be sustainable. About Aditxt Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com. NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

• Flora Growth Corp. announced that the Company Board has authorized the repurchase of up to $5 million of its outstanding common shares
• Luis Merchan, Flora’s Chairman and CEO, said that Flora is executing its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses
• At the closing of 2021, the company announced a 2022 revenue guidance projection of $35-45 million

Flora Growth (NASDAQ: FLGC) is a global leader in the cultivation, marketing, and distribution of premium-quality cannabis products and brands at below-market prices. Flora Growth recently announced that the company’s Board of Directors (the “Board”) has authorized the repurchase of up to $5 million of its outstanding common shares subject to market conditions and the company’s liquidity warrant (https://ibn.fm/MN24h). Luis Merchan, Flora’s Chairman and CEO, stated that the potential to repurchase their shares at these levels represents a compelling opportunity to deploy available cash to drive shareholder value. The company’s board believes that the decline in the market price of shares is due to the generally weak financial market and cannabis sector. It is also attributed to the recent selling of several millions of shares by certain shareholders who acquired such shares at a very low-cost basis, prior the company’s had its IPO, and who had previously been subject to a one-year lockup period which expired in mid-May. Repurchases may be made from time to time through open market purchases, and, in no event shall the company repurchase more than five percent of the total number of issued and outstanding shares as of the repurchase date. Flora’s 249-acre cultivation facility Cosechemos, based in Colombia, is the core of the company’s business model. The ideal location, resources, and climatic conditions at the Cosechemos farm, enable Flora’s low production cost which is approximately $0.06/gram, compared to production costs that can be as high as $1/gram or more in parts of North America (https://ibn.fm/AmzIv). On Feb 22, 2022, Columbia’s President Duque approved a previously announced legislation expanding on Resolution 811.  The new Resolution 227 allows the industrial use of cannabis in sectors such as food, beverages and textile. This new regulation will further pave way for increased revenues for the company (https://ibn.fm/IKQjp). Recently, Flora also solidified its foothold in the U.S., by acquiring the luxury cannabis consumer brand Vessel Brand Inc. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• SGMD will produce an estimated 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines
• The market for Fresh Frozen cannabis is “snowballing,” says Cannabis Global CEO
• With the rapid Fresh Frozen harvesting process, airtight storage and near cryogenic storage temperatures, almost all of the natural cannabis plant essence is preserved

Sugarmade (OTC: SGMD), an emerging leader in the licensed cannabis sector, is seeing the fruit of its labors, so to speak. The company recently announced the first transaction under its previously announced contract with Cannabis Global (OTC: CBGL). The transaction calls for Sugarmade to produce an estimated 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines and will distribute to the California marketplace (https://ibn.fm/l3QJa). Sugarmade and Cannabis Global have signed a prebooked, fixed-price contract in the amount of $700,000; that payment includes cash payments from Cannabis Global to Sugarmade of $300,000 and notes for the balance of $400,000. Planting of the cultivators began in mid-May and will continue into early June. “The market for Fresh Frozen cannabis is snowballing,” said Cannabis Global CEO Arman Tabatabaei. “Thus we believe it is the place to be for the 2022 cultivation season. We plan to process a large portion of the 25,000 pounds of ultra-premium cannabis at our Lynwood, California, laboratory, creating premium solventless extracts for sale into the market and for use in our own manufactured products, thus creating vertical integration to reduce our costs of goods sold. “We also plan to store a significant portion of the biomass in the Los Angeles area to create an active wholesale market to the many new solventless extractors in the area via our wholly owned distribution company, Northern Lights Distribution,” Tabatabaei continued. “We have integrated this cultivation effort into our strategic plan for 2022 and 2023 as an important component to further boost our already fast-growing revenue base.” Fresh Frozen cannabis is flash frozen immediately after harvest instead of undergoing the traditional treatment of drying and curing. A growing number of cannabis consumers are choosing this type of cannabis as they seek naturally produced cannabis products full of natural plant terpenes and flavors. As demand grows, the number of products available that contain Fresh Frozen cannabis is also growing. “In many ways, the advent of Fresh Frozen-oriented cannabis cultivation has turned the cannabis cultivation model on its head,” a recent article observed. “Where cultivators traditionally harvested cannabis plants and then spent weeks or months drying, curing and processing plant materials, all the while battling heat, humidity, molds and other factors that could affect the product. “Fresh Frozen-oriented cultivation allows growers to ditch the traditional model by cutting down the plants at the peak of freshness, stripping the large leaves, branches and stems and then bagging the remaining materials bound for storage in industrial freezers at temperatures well below -5 F,” the article continued. “With the rapid harvesting process, airtight storage and near cryogenic storage temperatures, almost all of the natural cannabis plant essence is preserved.” Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue and Lemon Glow. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• FingerMotion is a U.S.-based communications technology business focused on serving the enormous cell phone and reinsurance markets in China
• Company CEO Martin Shen recently reported on the growing operations of FingerMotion and the increase in annual revenues when he appeared at LD Micro’s annual investor-centric conference in California
• Shen noted that FingerMotion’s ultimate goal is to improve people’s lifestyles by using technology and data analysis to boost understanding, and creating new products that further develop that goal
• The company is expanding on its SMS, MMS and top-up revenue channels by developing RCS services and a device protection plan operation for the coming year

FingerMotion (NASDAQ: FNGR) continues to build a strong telecommunications revenue stream in mobile top-up, short and multimedia messaging (SMS and MMS) services for Chinese consumers while building new revenue channels in several of China’s provinces, particularly in rich communication services (“RCS”) that mark an evolution of SMS and MMS by drawing on the power of 5G wireless technology to expand marketing and purchasing services.

As an evolving communications and big data technology company, FingerMotion continues to seek new capital to fund its growing endeavors in China’s 1.6 billion-person mobile products and services market.

On June 8, FingerMotion CEO Martin Shen joined companies presenting information about their operations to peers and potential investors at the 12th Annual LD Micro Invitational Conference in the Greater Los Angeles area’s Westlake Village (https://ibn.fm/GA8SY), building on similar efforts that have taken place since FingerMotion listed its shares of common stock on the Nasdaq Capital Market in December (https://ibn.fm/1KImX).

“Our primary area of focus is the development of must-have application for consumers and businesses,” a promotional video introduced by Shen at the LD Micro conference stated.

“Hopefully you can see from that video that we’re well-entrenched in the mobile phone arena, particularly in the mobile data spaces,” Shen followed up. “With our data and our big data insights arm Sapientus we hope to fulfill our vision, which is to improve people’s lifestyle by understanding human behavior, by innovating new products, enhancing the products that already exist, and then hopefully with those consumer and understanding human behavior analytics we can improve lifestyle in general” (https://ibn.fm/yHeHK).

In China’s mobile phone use market, consumers continually run out of minutes and data allowances and have to “top up” to add more user time for themselves — a need FingerMotion was quick to satisfy.

“We’ve been doing this for about three years. We’re very confident in our platform — the Telcos are very happy because their consumers are happy,” Shen said.

FingerMotion’s SMS and MMS texting and video services have provided the bulk of its revenues, which overall grew $6.24 million, or 37 percent, from FY 2021 to FY 2022, as reported June 1 (https://ibn.fm/fGnen).

Regarding the RCS product, Shen said the company is in the process of developing it and hopes to launch it within the current fiscal year.

“We have a few expansion plans with some new funding, first of which, which is most exciting, is our device protection plan,” Shen said. “We’ll still continue to grow our RCS. … And finally we’ll continue to build out our big data and our Sapientus arm.”

The big data analyzed and developed through Sapientus has been directed to serving re-insurance companies operating in Asia since its launch last year.

“This year, we are just shy of $23 million in revenue, so you can see that the growth of the last four years has been quite substantial,” Shen said. “We’re excited about what the device protection plan can bring forward to us because we think that’s revenue where there’s very little cost associated with it — we’re just running it and we’re bringing the companies together that need to do it.”

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• New COVID-19 preparedness plan involves renewed focus on indoor air quality (“IAQ”)
• Initiative includes campaign to promote ways to improve IAQ as well as financial assistance to state, local governments and schools for HVAC system upgrades
• Kronos AIR 5G(R) Air Purifiers have been tested, confirmed as the most effective clean-air solution on the market

Indoor air quality (“IAQ”) is coming under closer scrutinization under the Biden administration, according to a new plan (https://ibn.fm/j3ixw). According to a recent White House fact sheet, “The Biden Administration and Congress have provided hundreds of billions of dollars in federal funds that can be used in schools, public buildings, and other settings to improve indoor air quality” (https://ibn.fm/FBk9k). The correlation between indoor air quality and good health is one that Kronos Advanced Technologies (OTC: KNOS) embraced long ago, as the company develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces. “The Biden administration plans a renewed focus on indoor air quality as part of its latest response to the ongoing coronavirus pandemic,” reported the ACHR News. “The White House’s IAQ initiative was broadly outlined in its 97-page National COVID-19 Preparedness Plan, which was issued in early March and referred to briefly by President Joe Biden in his State of the Union address. “Steps include a publicity campaign to promote ways to improve IAQ, financial assistance to state and local governments and schools for HVAC system upgrades, and a ‘Clean Air in Buildings Challenge’ to encourage building owners and managers and building engineers to adopt strategies to improve air quality in their buildings,” the article continued. “The plan pledges IAQ guidance and technical resources for such efforts.” According to the White House plan, “strong ventilation practices can reduce the number of virus particles and contaminants in the air, and thereby reduce the risk of virus or disease transmission.” The article noted that the Biden administration “will work with Congress to secure the necessary funding” for the initiatives, with state and local governments and school districts encouraged to use American Rescue Plan money to improve their air ventilation and filtration systems. Kronos Advanced Technologies stands to benefit from the new initiative. The company’s Kronos AIR 5G(R) Air Purifiers are some of the most powerful and effective air purifiers available today. The devices, which come in three models, feature Kronos’ own patented, medical-grade technology, which has been tested and confirmed as the most effective clean-air solution on the market. According to Kronos, its purifiers filter particles down to .0146 micron (.0146μm), far beyond the 3 microns (0.3μm) of a traditional HEPA filter. In addition, Kronos purifiers not only collect but also destroy 99.99% of all airborne bacteria, mold and virus particles. Unlike traditional HEPA systems that collect pollutants on filters, which can grow mold and bacteria with time, Kronos’ patented technology collects and eliminates harmful particles, depositing them on easy-to-clean collecting plates. This process reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month. KNOS recently acquired an 85,000-square-foot West Virginia manufacturing campus that will be retrofitted to produce advanced, proprietary air-purification devices and other wellness products (https://ibn.fm/TbuNb). For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

• Tens of millions of adults, children are living in food-insecure households
• Micro-farms, such as ACTX’s Grow Pods, are being evaluated as a potential solution for food insecurity
• With GrowPods, cultivation can be moved directly into the areas where food is needed

An estimated 30 million adults and 12 million children are living in food-insecure households, reports a recent CNN Business article (https://ibn.fm/nnECx). Those are people that Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of Grow Pods, believes it can help. “Families across America are precariously perched on the edge of a hunger cliff,” reports CNN Business. “With inflation on the rise and supply chain backlogs, more families have been turning to food banks, forcing programs nationwide to ration supplies and cut services. And now the war in Ukraine is leading to more food shortages and driving up prices even further. Now is not the time to turn our backs on those who cannot afford to put food on the table. “The U.S. Department of Agriculture (‘USDA’) has estimated that as many as 30 million adults and 12 million children are living in food-insecure households,” the CNN report continued. “And the U.S. Census Bureau’s Household Pulse Survey found that in the last seven days, 10.3% of respondents sometimes or often did not have enough to eat. Local food aid organizations are essential community resources for families during this crisis, but they cannot do it all by themselves.” Micro-farms, such as ACTX’s Grow Pods, are being evaluated as a potential solution for food insecurity. Last year, Virginia State University (“VSU”) was given a $600,000 grant to explore micro farms as a potential solution to what the school called “food deserts in urban neighborhoods” (https://ibn.fm/tSTxL). According to the school, the grant will build VSU’s capacity to provide comprehensive education on micro farming. Leonard Githinji, project director and sustainable and urban agriculture Cooperative Extension specialist at VSU, reports that more than 11% of the nation’s population and 10% of Virginia’s population are food insecure. “Residents in food-insecure areas, commonly known as food deserts, have little or no access to fresh, affordable and nutritious food, and often have higher instances of chronic diseases, such as obesity, due to poor diets,” Githinji states. “Developing sustainable micro farms in urban areas can have a profound impact on access to healthy food in food deserts.” The funding will enhance VSU’s capacity to study micro farming and provide experiential learning and hands-on training to students, extension agents, master gardeners and youth leaders. Companies operating in the micro-farming space, such as Advanced Container Technologies, will also likely benefit from the study results. The three-year study will focus on developing and optimizing environmental growing conditions so that research-based information can be disseminated on best practices for micro farming. ACTX is confident its GrowPods — modular hydroponic greenhouses — could become a valuable tool in efforts to combat food insecurity. “With GrowPods, cultivation can be moved directly into the areas where food is needed,” the company noted (https://ibn.fm/tiWZK). “Additionally, locating the pods nearer to the point of consumption allows food to be harvested at its peak nutritional value, and greatly reduces the carbon and environmental impact of the nation’s current food chain, which relies on trucks carrying mass quantities of produce across the country.” GrowPods offer a controlled environment with major advantages for the production of high-value crops. The ability to grow crops year-round while cultivating in a smaller footprint using less resources make the systems particularly well suited for programs such as the LFPA. ACTX is the exclusive distributor of GrowPods in certain markets. The company also provides a variety of other products and services, including packaging solutions for medicinal, pharmaceutical, and agricultural products. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com. NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://ibn.fm/ACTX